| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
11,820 |
6,592 |
$411K |
| 90686 |
|
23,185 |
17,017 |
$225K |
| 0001A |
|
1,343 |
1,061 |
$26K |
| 0002A |
|
1,370 |
1,101 |
$25K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,515 |
2,079 |
$12K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
1,256 |
1,093 |
$5K |
| 0012A |
|
671 |
642 |
$5K |
| 0031A |
|
487 |
450 |
$3K |
| 90656 |
|
233 |
230 |
$3K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
878 |
823 |
$2K |
| 0124A |
|
139 |
130 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,442 |
1,482 |
$1K |
| 0011A |
|
208 |
198 |
$1K |
| 0052A |
|
52 |
42 |
$1K |
| G0008 |
Administration of influenza virus vaccine |
3,119 |
2,951 |
$1K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
90 |
83 |
$998.41 |
| 0051A |
|
33 |
30 |
$950.34 |
| 0053A |
|
47 |
40 |
$880.00 |
| 87428 |
|
79 |
79 |
$809.35 |
| 99401 |
|
510 |
349 |
$800.00 |
| 0072A |
|
33 |
26 |
$720.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
637 |
574 |
$595.96 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
638 |
576 |
$595.96 |
| 0071A |
|
24 |
16 |
$560.00 |
| 0134A |
|
56 |
52 |
$520.00 |
| 0073A |
|
21 |
12 |
$480.00 |
| 90672 |
|
63 |
28 |
$458.88 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
452 |
391 |
$397.28 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
163 |
158 |
$256.63 |
| 81025 |
|
649 |
509 |
$199.95 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
10,987 |
8,314 |
$144.77 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
560 |
538 |
$138.96 |
| 99402 |
|
223 |
156 |
$133.65 |
| 86703 |
|
14 |
13 |
$50.14 |
| 90480 |
|
191 |
178 |
$33.20 |
| 86592 |
|
299 |
287 |
$24.85 |
| 91300 |
|
2,161 |
1,757 |
$10.05 |
| 87210 |
|
37 |
24 |
$6.10 |
| 91307 |
|
675 |
440 |
$2.79 |
| 91301 |
|
937 |
890 |
$1.67 |
| 91305 |
|
201 |
173 |
$1.21 |
| 91303 |
|
474 |
438 |
$0.67 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
25 |
17 |
$0.65 |
| 91312 |
|
144 |
135 |
$0.47 |
| 91313 |
|
58 |
54 |
$0.13 |
| 91322 |
|
179 |
166 |
$0.00 |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
30 |
19 |
$0.00 |
| 90662 |
|
44 |
42 |
$0.00 |
| 90473 |
|
21 |
13 |
$0.00 |
| 11981 |
|
30 |
19 |
$0.00 |
| 90632 |
|
125 |
118 |
$0.00 |
| 86803 |
|
19 |
13 |
$0.00 |